Actinium Submits CMC Meeting Request to FDA for Iomab-B to Support IND Filing and Anticipated Commencement of Phase 3 Trial in Mid-2015

um Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a CMC (Chemistry, Manufacturing and Control) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently undergoing preparations for starting the pivotal Phase 3 trial by the middle of 2015. The Company expects to obtain further guidance from the FDA that will allow completion of the processes and methods for large scale manufacturing and testing of clinical and commercial grade drug product. "We are now in the final stages in our preparations to commence the Phase 3 trial for Iomab-B while simultaneously establishing the necessary infrastructure to enable the Company to quickly commercialize Iomab-B, if approved by FDA," said Kaushik J. Dave, President and Chief Executive Officer of Actinium Pharmaceuticals, Inc. "We believe input from the FDA will be invaluable as we finalize our proprietary manufacturing processes to support both the clinical trials and future commercialization."